Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension

American Heart Journal

Volumn 156, Issue 6, 2008, Pages 1154.e1-1154.e8

  Napoli, Claudio ^a,b   Bruzzese, Giuseppe ^c   Ignarro, Louis J ^d   Crimi, Ettore ^e   de Nigris, Filomena ^a   Williams Ignarro, Sharon ^d   Libardi, Sabina ^b   Sommese, Linda ^a   Fiorito, Carmela ^b   Mancini, Francesco P ^f   Cacciatore, Francesco ^g   Liguori, Antonio ^c  

^a Excellence Research Center on Cardiovascular Diseases   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c Pellegrini Hospital   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF SANNIO   (Italy)

^g IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ISOPROSTANE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; THIOL DERIVATIVE; ZOFENOPRIL;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONG TERM CARE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 56649092793     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.09.006     Document Type: Article

References (57)

1. Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs 7 (2007) 17-24
2. Napoli C., and Loscalzo J. New challenges for ACE-inhibitors in vascular diseases. Drug Design Rev 2 (2005) 485-493
3. Napoli C., Sica V., Pignalosa O., et al. New trends in anti-atherosclerotic agents. Curr Med Chem 12 (2005) 1755-1772
4. Pasini A.F., Garbin U., Nava M.C., et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 20 (2007) 443-450
5. Powell J.S., Clozel J.P., Müller R.K., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 (1989) 186-188
6. Janiak P., Libert O., and Vilaine J.P. Role of the renin-angiotensin system in neointima formation after injury in rabbits. Hypertension 24 (1994) 671-678
7. Fennessy P.A., Campbell J.H., and Campbell G.R. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis 106 (1994) 29-41
8. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
9. Napoli C., Cicala C., D'Armiento F.P., et al. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in Watanabe heritable hyperlipidemic rabbits. Gen Pharmacol 33 (1999) 467-477
10. Chobanian A.V., Haudenschild C.C., Nickerson C., et al. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15 (1990) 327-331
11. Aberg G., and Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 15 (1990) S65-S72
12. Hayek T., Attias J., Smith J., et al. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 31 (1998) 540-544
13. de Nigris F., D'Armiento F.P., Somma P., et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 81 (2001) 107-115
14. Sun Y.P., Zhu B.Q., Browne A.E., et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 6 (2001) 175-181
15. Charpiot P., Rolland P.H., Friggi A., et al. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler Thromb 13 (1993) 1125-1138
16. Candido R., Jandeleit-Dahm K.A., Cao Z., et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106 (2002) 246-253
17. Kowala M.C., Grove R.I., and Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 108 (1994) 61-72
18. Hayek T., Attias J., Coleman R., et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 44 (1999) 579-587
19. Li J., Hirose N., Kawamura M., et al. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 143 (1999) 315-326
20. Keidar S., Attias J., Coleman R., et al. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J Cardiovasc Pharmacol 35 (2000) 64-72
21. Hayek T., Kaplan M., Raz A., et al. Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis 161 (2002) 65-74
22. Bonithon-Kopp C., Ducimetière P., Touboul P.J., et al. Plasma angiotensin-converting enzyme activity and carotid wall thickening. Circulation 89 (1994) 952-954
23. MacMahon S., Sharpe N., Gamble G., et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease: PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 36 (2000) 438-443
24. Teo K.K., Burton J.R., Buller C.E., et al. Long-term effects of cholesterol lowering, and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial. Circulation 102 (2000) 1748-1754
25. Asselbergs F.W., van Roon A.M., Hillege H.L., et al. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke 36 (2005) 649-653
26. Zanchetti A., Crepaldi G., Bond M.G., et al., on behalf of PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS-a randomized double-blind trial. Stroke 35 (2004) 2807-2812
27. Lonn E.M., Yusuf S., Dzavik V., et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 103 (2001) 919-925
28. Unger T. the role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89 (2002) 3A-10A
29. Jacoby D.S., and Rader D.J. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 163 (2003) 1155-1164
30. Scribner A.W., Loscalzo J., and Napoli C. The effect of angiotensin converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 482 (2003) 95-99
31. Napoli C., Sica V., de Nigris F., et al. Sulfhydryl ACE inhibition induces a sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 148 (2004) e5-e13
32. Evangelista S., and Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 33 (2005) 42-54
33. Cominacini L., Pasini A., Garbin U., et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 15 (2002) 891-895
34. Grobbee D.E., and Bots M.L. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 263 (1994) 567-573
35. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Eng J Med 340 (1999) 14-22
36. Napoli C., Lerman L.O., de Nigris F., et al. Rethinking primary prevention of atherosclerosis-related diseases. Circulation 114 (2006) 2517-2527
37. Napoli C., Liguori A., Sorice P., et al. Relations between vasoactive hormonal factors and left ventricular diastolic function in normotensive and hypertensive uremics. J Intern Med 240 (1996) 389-394
38. Persson J., Stavenow L., Wikstrand J., et al. Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurements of arterial wall thickness and plaque size. Arterioscler Thromb 12 (1992) 261-266
39. Burke G.L., Evans G.W., Riley W.A., et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 26 (1995) 386-391
40. Allan P.L., Mowbray P.I., Lee A.J., et al. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease: the Edinburgh Artery Study. Stroke 28 (1997) 348-353
41. Yusuf S., Sleight P., Pogue J., et al., for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
42. Wang J.G., Staessen J.A., Li Y., et al. Carotid intima-media thickness and antihypertensive treatment. A meta-analysis of randomized controlled trials. Stroke 37 (2006) 1933-1940
43. Hosomi N., Mizushige K., Ohyama H., et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 32 (2001) 1539-1545
44. Espeland M.A., Craven T.E., Riley W.A., et al., for the Asymptomatic Carotid Artery Progression Study Research Group. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Stroke 27 (1996) 480-485
45. Glagov S., Weisenberg E., Zarins C.K., et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 (1987) 1371-1375
46. Cashin-Hemphill L., Holmvang G., Chan R.C., et al. for the QUIET Investigators (Quinapril Ischemic Event Trial). Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Am J Cardiol 83 (1999) 43-47
47. Hornig B., Arakawa N., Haussmann D., et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 98 (1998) 2842-2848
48. Burnier M., and Zanchi A. Blockade of renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 24 (2006) 11-25
49. Kurtz T.W., and Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 22 (2004) 2253-2261
50. Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685
51. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343 (1994) 1115-11122
52. Mak I.T., Freedman A.M., Dickens B.F., et al. Protective effects of sulfhydryl-containing angiotensin-converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 40 (1990) 2169-2175
53. Ambrosioni E., Borghi C., and Magnani B. The effect of angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332 (1995) 80-85
54. Borghi C., Bacchelli S., Esposti D.D., et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 12 (1999) 665-672
55. Borghi C., and Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-Term Evaluation-2 (SMILE-2) study. Am Heart J 145 (2003) 80-87
56. Napoli C., and Ignarro L.J. Nitric oxide and atherosclerosis. Nitric Oxide 5 (2001) 88-97
57. Furuki K., Adachi H., Matsuoka H., et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. An epidemiological study. Atherosclerosis 191 (2007) 206-210